



NEWS RELEASE AUGUST 3rd, 2009

Occlutech wins against AGA in the UK

Occlutech, the leading European developer of septum occluders, today announced that it got a favorable ruling in the litigation with AGA Medical in the UK. On Friday July 31st the High Court of London announced that Occlutech is not infringing the relevant AGA Medical patent.

The historical unfavorable decisions from Germany were analyzed in detail and clearly considered wrong by the High Court. AGA was not granted permission to appeal.

AGA's patent was not invalidated which means that AGA and Occlutech together hold a strong position against any third party.

The ruling clearly shows that Occlutech has a unique technology.

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.

Tor Peters
+41 79 457 52 47
Tor.peters@occlutech.com

Susanne Goransson
+46 704 33 65 21
Susanne.goransson@occlutech.net